Oncolytics Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. 

CEO
Jared Kelly
CEOJared Kelly
Employees
29
Employees29
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
29
Employees29

ONCY Key Statistics

Market cap
106.42M
Market cap106.42M
Price-Earnings ratio
-3.69
Price-Earnings ratio-3.69
Dividend yield
Dividend yield
Average volume
1.86M
Average volume1.86M
High today
$0.9959
High today$0.9959
Low today
$0.88
Low today$0.88
Open price
$0.95
Open price$0.95
Volume
1.05M
Volume1.05M
52 Week high
$1.51
52 Week high$1.51
52 Week low
$0.3258
52 Week low$0.3258

Stock Snapshot

The current Oncolytics Biotech(ONCY) stock price is $0.89, with a market capitalization of 106.42M. The stock trades at a price-to-earnings (P/E) ratio of -3.69.

On 2026-06-03, Oncolytics Biotech(ONCY) stock traded between a low of $0.88 and a high of $1.00. Shares are currently priced at $0.89, which is +1.3% above the low and -10.5% below the high.

Oncolytics Biotech(ONCY) shares are trading with a volume of 1.05M, against a daily average of 1.86M.

During the past year, Oncolytics Biotech(ONCY) stock moved between $0.33 at its lowest and $1.51 at its peak.

During the past year, Oncolytics Biotech(ONCY) stock moved between $0.33 at its lowest and $1.51 at its peak.

ONCY News

Simply Wall St 11h
Why Oncolytics Biotech Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data

In late May and early June 2026, Oncolytics Biotech reported new preclinical and translational data showing pelareorep’s enhanced anti-tumor activity and multi-...

Why Oncolytics Biotech Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data
Barchart 1d
Signs of Abundant Global Supplies Undercut Sugar Prices - Barchart.com

...

Signs of Abundant Global Supplies Undercut Sugar Prices - Barchart.com
TipRanks 1d
Oncolytics promotes John McAdory to COO

Oncolytics (ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to COO. Additionally, McAdory has been p...

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

More ONCY News

TipRanks 1d
Oncolytics Biotech Strengthens Leadership with New COO, Director

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 2d
Oncolytics announces initial data from pelareorep combination study

Oncolytics (ONCY) announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, whi...

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.